| Literature DB >> 30744659 |
Florian Milatz1, Jens Klotsche2, Martina Niewerth2, Nils Geisemeyer2, Ralf Trauzeddel3, Elisabeth Weißbarth-Riedel4, Tilmann Kallinich5, Joachim Peitz6, Matthias Hartmann7, Kirsten Minden8.
Abstract
BACKGROUND: Regular school sports can help adolescents achieve the recommended amount of daily physical activity and provide knowledge, attitudes and behavioral skills that are needed in order to adopt and maintain a physically active lifestyle. Furthermore, it reaches all children including those that are at risk for engaging in more sedentary types of behavior. Since adolescents with juvenile idiopathic arthritis (JIA) are less involved in physical and social activities than their healthy peers, the objectives were to (1) estimate the prevalence of participation in school sports among patients with JIA; (2) determine the correlates associated with school sports absenteeism; and (3) investigate whether attendance in school sports has changed in the era of biologics.Entities:
Keywords: Children and adolescents; Correlates; Juvenile idiopathic arthritis; Participation; Prevalence; School sports; Trends
Mesh:
Year: 2019 PMID: 30744659 PMCID: PMC6371582 DOI: 10.1186/s12969-019-0306-9
Source DB: PubMed Journal: Pediatr Rheumatol Online J ISSN: 1546-0096 Impact factor: 3.054
Characteristics of school-aged JIA patients recorded in the years 2000, 2003, 2006, 2009, 2012, and 2015
| 2000 | 2003 | 2006 | 2009 | 2012 | 2015 | |
|---|---|---|---|---|---|---|
| No. of patients | 1463 | 2339 | 3020 | 3526 | 3722 | 5879 |
| Age, years | 12.3 ± 3.2 | 12.6 ± 3.3 | 12.7 ± 3.4 | 12.6 ± 3.3 | 13.7 ± 2.5 | 13.1 ± 3.3 |
| BMI, kg/m2 | ─ | 19.4 ± 3.8 | 19.4 ± 3.9 | 19.4 ± 4.8 | 19.7 ± 2.8 | 19.1 ± 3.2 |
| Female, no. (%) | 898 (61.4) | 1464 (62.4) | 1901 (62.9) | 2246 (63.7) | 2374 (63.8) | 3844 (65.4) |
| Disease duration, years | 4.9 ± 3.6 | 5.5 ± 3.3 | 5.3 ± 3.5 | 5.1 ± 3.3 | 5.5 ± 3.6 | 5.9 ± 4.0 |
| Age at disease onset, years | 7.4 ± 4.1 | 7.7 ± 4.2 | 7.7 ± 4.3 | 7.8 ± 4.2 | 8.5 ± 4.2 | 7.9 ± 4.4 |
| JIA category, no. (%) | ||||||
| RF-positive polyarthritis | 51 (3.5) | 59 (2.5) | 65 (2.2) | 99 (2.8) | 114 (3.1) | 145 (2.5) |
| RF-negative polyarthritis | 206 (14.1) | 9 (12.3) | 461 (15.3) | 495 (14.0) | 645 (17.3) | 1084 (18.4) |
| Systemic JIA | 105 (7.2) | 127 (5.4) | 150 (5.0) | 164 (4.7) | 128 (3.4) | 264 (4.5) |
| Persistent oligoarthritis | 526 (36.0) | 943 (40.2) | 1238 (41.0) | 1637 (46.4) | 1479 (39.7) | 2165 (36.9) |
| Extended oligoarthritis | 140 (9.6) | 157 (6.7) | 180 (6.0) | 225 (6.4) | 349 (9.4) | 652 (11.1) |
| Psoriatic arthritis | 133 (9.1) | 254 (10.8) | 275 (9.1) | 234 (6.6) | 225 (6.0) | 342 (5.8) |
| Enthesitis-related arthritis | 196 (13.4) | 400 (17.0) | 528 (17.5) | 570 (16.2) | 664 (17.8) | 1052 (17.9) |
| Unclassified JIA | 106 (7.2) | 110 (4.7) | 123 (4.0) | 102 (2.9) | 118 (3.2) | 175 (2.9) |
| cJADAS-10 | 5.8 ± 5.5 | 4.3 ± 4.7 | 4.3 ± 4.8 | 4.0 ± 4.6 | 4.0 ± 4.7 | 4.0 ± 4.7 |
| PGA scoreφ | 1.7 ± 1.7 | 1.3 ± 1.7 | 1.4 ± 1.7 | 1.3 ± 1.7 | 1.4 ± 1.8 | 1.2 ± 1.8 |
| Inactive disease*, no. (%) | 429 (30.0) | 952 (41.4) | 1229 (41.3) | 1444 (42.6) | 1423 (39.8) | 3130 (54.6) |
| No. of joints with active disease | 3.2 ± 5.7 | 1.6 ± 3.4 | 1.6 ± 3.6 | 1.5 ± 3.3 | 1.3 ± 3.2 | 1.1 ± 2.9 |
| ESR, mm/h | 10.7 ± 15.1 | 11.7 ± 12.5 | 12.6 ± 14.6 | 11.7 ± 12.6 | 10.1 ± 10.7 | 11.2 ± 12.8 |
| C-HAQ total score | 0.3 ± 0.5 | 0.2 ± 0.4 | 0.2 ± 0.4 | 0.2 ± 0.4 | 0.2 ± 0.4 | 0.2 ± 0.4 |
| No functional limitations†, no. (%) | 738 (51.3) | 1300 (55.8) | 1717 (58.8) | 2151 (61.4) | 2280 (61.8) | 3465 (59.9) |
| Patient-reported well-beingφ | 1.8 ± 2.1 | 1.7 ± 2.0 | 1.7 ± 2.0 | 1.6 ± 2.0 | 1.6 ± 2.1 | 1.8 ± 2.2 |
| Patient-reported painφ | 1.6 ± 2.3 | 1.6 ± 2.2 | 1.6 ± 2.2 | 1.6 ± 2.3 | 1.7 ± 2.5 | 1.8 ± 2.5 |
| Patient-reported fatigueφ | ─ | ─ | ─ | ─ | 1.5 ± 2.5 | 1.5 ± 2.5 |
| Patient-reported copingφ | 1.6 ± 0.9 | 1.6 ± 0.9 | 1.4 ± 2.1 | 1.4 ± 2.0 | 1.3 ± 2.1 | 1.4 ± 2.1 |
| Treatment in past 12 months, no. (%) | ||||||
| No systemic GCs | 1103 (78.8) | 1768 (81.3) | 2323 (85.2) | 2535 (88.5) | 2683 (89.4) | 4519 (92.4) |
| Low-dose GCs (< 0.2 mg/kg) | 244 (17.4) | 336 (15.4) | 343 (12.6) | 246 (8.6) | 258 (8.6) | 236 (4.8) |
| Combination of high-dose GCs/ | ||||||
| pulse therapy | 10 (0.7) | 11 (0.5) | 14 (0.5) | 16 (0.5) | 19 (0.5) | 29 (0.5) |
| Intra-articular GCs | 255 (18.2) | 195 (9.0) | 299 (11.0) | 317 (11.1) | 261 (8.7) | 434 (8.9) |
| Any conventional synthetic DMARD | 674 (48.9) | 1013 (48.6) | 1496 (56.0) | 1672 (54.7) | 1861 (58.0) | 1828 (30.7) |
| Any biologic DMARD | 11 (0.8) | 114 (11.3) | 295 (9.8) | 432 (14.1) | 650 (20.6) | 1140 (22.3) |
| Regular exercise in leisure time (patients aged ≥13)‡, no. (%) | ─ | ─ | 2174 (72.9) | 2677 (77.1) | 3029 (82.9) | 2409 (79.1) |
| Physical therapies, no. (%) | ||||||
| Physiotherapy | 972 (67.9) | 1299 (56.8) | 1645 (55.9) | 1714 (50.4) | 1844 (51.0) | 2830 (49.9) |
| Kinetotherapeutic bath | 132 (9.2) | 110 (4.8) | 130 (4.4) | 123 (3.6) | 96 (2.7) | 147 (2.6) |
| Occupational therapy | 119 (8.3) | 200 (8.7) | 316 (10.7) | 318 (9.3) | 381 (10.5) | 567 (10.0) |
| No physical therapy | 401 (28.0) | 903 (39.5) | 1177 (40.0) | 1557 (45.7) | 1679 (46.5) | 2687 (47.4) |
JIA juvenile idiopathic arthritis RF rheumatoid factor, cJADAS-10 10-joint clinical Juvenile Arthritis Disease Activity Score, PGA physician’s global assessment, ESR erythrocyte sedimentation rate, C-HAQ Childhood Health Assessment Questionnaire; GC, glucocorticoid, DMARD disease-modifying antirheumatic drug
*Defined by a PGA score of zero
†Defined by a C-HAQ score of zero
φAssessed on a numerical rating scale (maximum score 10) by patients aged ≥13
‡‘daily/3–5 times a week/1–2 times a week’ vs. ‘less than once a week/never’
Fig. 1School sports attendance and exemption rates in children and adolescents with JIA during the period 2000–2015. *significant time effect (attendance, p < 0.001; exemption, p < 0.001), adjusted for JIA category, disease duration, age at disease onset and sex
Fig. 2Sex-specific rates of full exemption from school sports in JIA patients during the period 2000–2015. *significant time effect (female, p < 0.001; male, p < 0.001)
Univariate and multivariable correlates of exemption from school sports in the 5879 patients recorded in the year 2015
| Variable | Univariate | Multivariable | ||||
|---|---|---|---|---|---|---|
| OR | 95% CI |
| OR | 95% CI |
| |
| Age | 1.11 | 1.09–1.14 | < 0.001 | 1.09 | 1.04–1.14 | < 0.001 |
| BMI | 1.07 | 1.05–1.10 | < 0.001 | 1.01 | 0.97–1.05 | 0.656 |
| Female sex | 1.30 | 1.11–1.52 | 0.001 | 1.00 | 0.78–1.28 | 1.000 |
| Disease duration | 0.99 | 0.99–1.00 | 0.049 | |||
| Age at disease onset | 1.08 | 1.06–1.10 | < 0.001 | 1.03 | 1.00–1.06 | 0.041 |
| RF-positive polyarthritis | 1.60 | 1.13–2.26 | 0.008 | 1.25 | 0.74–2.13 | 0.407 |
| RF-negative polyarthritis | 0.98 | 0.83–1.16 | 0.831 | 0.73 | 0.55–0.97 | 0.028 |
| Systemic JIA | 0.96 | 0.71–1.29 | 0.777 | 1.44 | 0.88–2.37 | 0.147 |
| Persistent oligoarthritis | 0.80 | 0.69–0.92 | 0.003 | 1.36 | 1.07–1.73 | 0.013 |
| Extended oligoarthritis | 1.07 | 0.88–1.31 | 0.487 | 1.29 | 0.95–1.76 | 0.097 |
| Psoriatic arthritis | 1.16 | 0.90–1.50 | 0.248 | 1.11 | 0.74–1.65 | 0.618 |
| Enthesitis-related arthritis | 0.85 | 0.71–1.02 | 0.075 | 0.71 | 0.52–0.96 | 0.028 |
| cJADAS-10 | 1.15 | 1.13–1.17 | < 0.001 | 1.08 | 1.03–1.13 | 0.001 |
| PGA score | 1.33 | 1.29–1.38 | < 0.001 | |||
| Inactive disease* | 0.28 | 0.24–0.33 | < 0.001 | |||
| No. of joints with active arthritis | 1.10 | 1.08–1.12 | < 0.001 | |||
| ESR | 1.02 | 1.02–1.03 | < 0.001 | |||
| C-HAQ total score | 1.13 | 1.11–1.15 | < 0.001 | 1.85 | 1.39–2.45 | < 0.001 |
| No functional limitations† | 0.24 | 0.21–0.28 | < 0.001 | |||
| Overall well-beingφ | 1.30 | 1.27–1.34 | < 0.001 | |||
| Pain intensityφ | 1.25 | 1.22–1.28 | < 0.001 | 1.04 | 0.97–1.11 | 0.265 |
| Fatigueφ | 1.17 | .14–1.20 | < 0.001 | 0.97 | 0.92–1.02 | 0.235 |
| Copingφ | 1.28 | 1.24–1.32 | 0.001 | 1.05 | 0.98–1.13 | 0.191 |
| Treatment in past 12 months | ||||||
| Any systemic GCs | 1.35 | 0.91–2.01 | 0.137 | |||
| Low-dose GCs (< 0.2 mg/kg) | 2.06 | 1.43–2.96 | < 0.001 | |||
| Any high-dose GCs (> 0.2 mg/kg)≠ | 1.90 | 1.36–2.67 | < 0.001 | |||
| Intra-articular GCs | 1.97 | 1.55–2.51 | < 0.001 | 1.52 | 1.08–2.15 | 0.017 |
| Any DMARD | 1.67 | 1.42–1.97 | < 0.001 | 1.70 | 1.33–2.19 | < 0.001 |
| Parent with academic degree | 1.31 | 1.02–1.67 | 0.035 | |||
| Regular exercise in leisure time (patients aged ≥13)‡ | 0.46 | 0.38–0.57 | < 0.001 | |||
| Physiotherapy | 1.88 | 1.62–2.18 | < 0.001 | 1.27 | 1.01–1.60 | 0.040 |
| Occupational therapy | 1.54 | 1.24–1.92 | < 0.001 | 0.96 | 0.66–1.39 | 0.819 |
| No physical therapy | 0.55 | 0.47–0.64 | < 0.001 | |||
OR odds ratio, 95% CI 95% confidence interval, RF rheumatoid factor, JIA juvenile idiopathic arthritis, JADAS-10 10-joint Juvenile Arthritis Disease Activity Score, PGA physician’s global assessment, ESR erythrocyte sedimentation rate, C-HAQ Childhood Health Assessment Questionnaire, GCs glucocorticoids, DMARD disease-modifying antirheumatic drug
* Defined by a PGA score of zero
† Defined by a C-HAQ score of zero
φ Assessed on a numerical rating scale (maximum score 10)
≠ Defined as high dose GCs (≥ 0.2 mg/kg) and/or intravenous pulse therapy
‡ ‘daily/3–5 times a week/1–2 times a week’ vs. ‘less than once a week/never’
Fig. 3Sex-specific rates of full exemption from school sports by JIA category in the year 2015. a) patients aged under 13, b) patients aged 13 and above